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Background: Aurora kinase A (AurkA) is over-expressed in melanoma and its inhibition has been observed to limit
tumor growth, suggesting a potential role in melanoma treatment.
Methods: A human melanoma cell line with the B-RAF (V600E) mutation (A375mel) was exposed to B-RAF inhibitor
(GSK2118436), MEK inhibitor (GSK1120212) and AurkA inhibitor (MLN8054) as single agents or in various combinations
(BRAF plus AurkA inhibitor, MEK plus AurkA inhibitor or triple combination BRAF plus MEK plus AurkA inhibitor).
Cell proliferation was assessed using xCELLigence technology. Total protein extracts were examined for p53 and
c-Myc protein expression by Western blot analysis. Drug anti-tumor effects were further assessed using a 3D-human
melanoma skin reconstruction model, in which tissues were incubated with serum-free medium containing control,
B-RAF plus MEK inhibitor, MEK plus AurkA inhibitor or the triple combination.
Results: AurkA inhibitor plus B-RAF inhibitor, AurkA inhibitor plus MEK inhibitor or triple combination had a markedly
greater anti-proliferative effect on A375 (BRAFV600E) melanoma cells than single agents. In the 3D human skin model,
the triple combination had a greater anti-tumor effect at the epidermal/dermal junction than control or either double
combination. However, S-100 and Ki-67 positively stained spindle-shaped cells were detected in the dermal stratum,
suggesting the presence of alive and proliferating melanoma cells.
Conclusions: These findings provide new prospects for melanoma research, including combined B-RAF/AurkA inhibition
for B-RAF mutated melanomas and MEK/AurkA inhibitor combination for patients without B-RAF mutations. Moreover,
for the first time, we have shown that a B-RAF, MEK and AurkA inhibitor triple drug combination offers increased efficacy
against melanoma cell growth and might be considered as a potential treatment strategy for enhancing clinical
response in melanoma. However, although this triple drug combination was more effective at the epidermal/dermal
junction, the suggested presence of alive and proliferating melanoma cells in the dermal stratum could result in drug
resistance and disease recurrence. Molecular characterization of these dermal cells may be critical for the development
of novel therapeutic strategies.
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Melanoma is a highly aggressive skin cancer originating
from melanocytes that is dramatically increasing in inci-
dence worldwide [1,2]. Several molecular alterations as-
sociated with melanoma have been identified and have
provided new targets for therapy. In particular, gene mu-
tations in the RAS/RAF/MEK/ERK or mitogen-activated
protein kinase (MAPK) pathway have been found to be
highly prevalent in melanomas. For example, around 40
different mutations in the B-RAF gene, encoding for a
serine-threonine kinase, have been identified. The most
frequent activating mutation (V600E-B-RAF) has been
found in exon 15 and results in the substitution of valine
for glutamic acid at position 600 of the BRAF protein
[3,4]. This mutation represents around 90% of BRAF mu-
tations described in melanoma and occurs in approxi-
mately 50% of melanoma cases [5]. Melanomas carrying a
B-RAF V600E mutation constitutively activate the MAPK
pathway, promoting cell proliferation and preventing
apoptosis [6]. Mutations in the NRAS gene have also
been observed in approximately 15-20% of melanomas
[7-9]. In addition, molecular alterations in the c-KIT and
GNαQ genes have been described, primarily in mucosal
and uveal melanoma subtypes, respectively [10].
B-RAF (V600E) inhibitors (e.g. vemurafenib, dabrafenib)
[11] were the first targeted therapy in melanoma and have
been associated with significant improvements in both
progression-free survival and overall survival compared
with chemotherapy in patients with B-RAF mutated meta-
static melanoma [12-16]. However, although B-RAF in-
hibitor therapy produced tumor responses in the majority
of patients and prolonged median survival, responses were
largely partial, and clinical evidence of tumor resistance
typically developed at a median of 5–7 months [17,18].
The different resistance mechanisms following B-RAF in-
hibitor treatment are a consequence of the activation of
alternative pathways, which can be classed as MAPK-
dependent [19] or MAPK-independent [20,21]. Acquired
resistance to B-RAF inhibitors has been reported to pri-
marily result from MAPK reactivation, driven by second-
ary mutations in NRAS and MEK1 genes in a subset of
melanoma patients [19]. Based on these data, the combin-
ation of a B-RAF inhibitor with an inhibitor of the MAPK
pathway downstream from BRAF, such as a MEK inhibitor
(e.g. trametinib), has been proposed in order to overcome
acquired B-RAF inhibitor resistance.
It has been observed that MEK inhibition leads to de-
creased cell signaling and proliferation in cancer cells
[22,23]. In particular, human melanoma cell lines with
N-RAS and B-RAF mutations seem to be more sensitive
to MEK inhibitor treatment than melanoma cell lines
with a B-RAF-mutation only [24]. While MEK inhibitor
treatment is associated with improved response rate,
progression free-survival and overall survival in patientswith B-RAF mutant metastatic melanoma, combined
B-RAF and MEK inhibitor treatment seems to provide
greater improvements in progression-free survival and
overall survival compared with B-RAF inhibitor mono-
therapy [25]. The observation that accelerated growth
of lesions harboring H-RAS mutations following expos-
ure to B-RAF inhibitors was blocked by subsequent
combined B-RAF/MEK inhibitor treatment is of par-
ticular note [26], and further supports the efficacy of
MEK inhibitors and their potential role in metastatic
melanoma [27,28].
Aurora kinase A (AurkA), one of the key regulators of
M phase progression, has been shown to be expressed
at high levels in melanoma [29]. AurkA is a member of
a serine/threonine kinase family consisting of three clas-
ses (Aurk A, B, and C) that are essential components of
the mitotic pathway [30]. They ensure proper chromo-
some assembly, formation of the mitotic spindle, and
cytokinesis. Over-expression of these kinases has been
observed in several tumor types, including colon, breast,
prostate, pancreas, thyroid, and head and neck, and is
associated with advanced clinical stage and poor prog-
nosis [31-33]. AurkA inhibition has been shown to limit
tumor growth, impair mitosis and induce senescence in
melanoma, suggesting a potential role in the treatment
of these tumors [34].
In this study, we assessed the anti-tumor effects of an
Aurk A inhibitor, B-RAF inhibitor and MEK inhibitor as
single agents and in various combinations in a B-RAF
(V600E) mutated human melanoma cell line and a three-
dimensional (3D) human skin reconstruction model in
order to provide a basis for further development of novel
therapeutic strategies in the treatment of melanoma.Methods
Inhibitor drugs
AurkA inhibitor (MLN8054) was purchased from Selleck
Chemicals (Munich, Germany), while GSK2118436 (B-RAF
inhibitor) and GSK1120212 (MEK inhibitor) were kindly
provided by Glaxo SmithKline (London, UK). The B-RAF
and MEK inhibitors were tested at a concentration of
30 nM in all experiments while the AurkA inhibitor
was tested at a concentration of 1 μM concentration.Cell lines and reagents
A human melanoma cell line with the B-RAF (V600E)
mutation (A375mel) was kindly provided by Dr. M. Bettinotti
(NIH, Bethesda, USA). The cells were cultured in RPMI
1640 medium (Lonza, Milan, Italy), supplemented with
3 mM L-glutamine (Invitrogen-Gibco®/Life Technologies,
Monza, Italy), 2% penicillin/streptomycin and 10% fetal
bovine serum (FBS). All cultures were incubated at 37°C
in a humidified 5% CO2 atmosphere.
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Cell proliferation was assessed using E-16-well plates
and the xCELLigence technology (Acea Bioscience, San
Diego, CA, USA, distributed by Roche Diagnostics) [35].
Briefly, cells (1 × 103 A375 cells/well) were seeded in
E-16-well plates in complete medium and grown for
48 hours. Inhibitor drugs were then added as single
agents or in different combinations (B-RAF inhibitor
[GSK2118436] plus MEK inhibitor [GSK1120212], BRAF
inhibitor plus AurkA inhibitor [MLN8054], MEK inhibitor
plus AurkA inhibitor [MLN8054] or triple-combination
of all three drugs) and the cell growth was monitored
for an additional 72 hours. Microelectrodes, placed on
the bottom of plates, were used to detect impedance
changes proportional to the number of adherent cells
and expressed as the cell index. The impedance value of
each well was automatically monitored by the xCELLigence
system and expressed as a cell index value. Doubling times
for each cell line were calculated from the cell growth curve
during the exponential phase. The experiments were
conducted in triplicate and repeated twice.
Western blot analysis
Western blot was performed according to standard proce-
dures. Mouse monoclonal antibody against p53 (DO-1;
diluted 1:1000) (Santa Cruz Biotechnology, Inc. Dallas,
TX, USA), rabbit antibody monoclonal to c-Myc (1:5000;
Abcam, Cambridge, UK), and rabbit polyclonal antibody
against β-actin (1:1000, Cell Signaling Technology,
Danvers, MA, USA) were used. Detection was achieved
by HRP-conjugated anti-mouse (Biorad, Hercules, CA,
USA, 1:2,000) or HRP-conjugated anti-rabbit (Cell Signal-
ing Technology, 1:1000) antibodies. Immune complexes
were visualized by an enhanced chemiluminescence
system (ECL Advance™, Amersham Pharmacia Biotech,
Piscataway, NJ, USA). Actin was used as a loading control.
The image analysis was performed by ImageJ software
(http://rsbweb.nih.gov/ij/). Results represent the means
(±SEM) of three independent experiments performed in
triplicate. P-values were determined by using t-tests and
a value ≤0.005 is reported (in figures with the symbol ***).
3D human skin reconstruction model
A 3D culture system of a differentiated and full-thickness
skin reconstruction model of A375 melanoma cells was
purchased from MatTek (Ashland, MA, USA). The 3D
tissues were fed through the basolateral (bottom) surface,
and incubated in duplicate with serum-free medium con-
taining DMSO 0.2% as control, B-RAF inhibitor plus
MEK inhibitor, MEK inhibitor plus AurkA inhibitor or a
triple-combination of all three drugs.
The medium was replenished every other day, and the
3D tissues were collected on days 0, 5, 9 and 12 from the be-
ginning of treatment and fixed with 4% paraformaldehyde.Tissues were paraffin-embedded, serial-sectioned, deparaf-
finized in xylene and rehydrated through graded decreas-
ing concentrations of alcohol. Finally, sections were
stained by hematoxylin and eosin (H&E) for cell morph-
ology analysis. For immunohistochemistry, antigen re-
trieval was carried out in citrate buffer (pH6) by heating
in a pressure cooker. The sections were then stained
with antibodies specific for the detection of S-100
(rabbit polyclonal; Dako, Milan, Italy) and Ki-67 (Mib-
1clone; Dako). Appropriate positive and negative controls
were included for each antibody test. Serial sections,
stained with H&E, S100 and Ki-67 were observed
under a 10x/0.30 NA and 40x/0.75 NA objective lens,
using a DM6000B upright microscope (Leica Microsys-
tems, Milan, Italy). Images were captured using a high-
resolution Leica DFC480 camera and digitally transferred
by the Leica Application Suite 4.0 software. AdobePhoto-
shop CS5 software was used for image analysis. Ki-67 and
S-100 positively stained cells were counted in six different
fields on each slide (observed under a 40x/0.75 NA object-
ive lens using the Leica DM6000B microscope) and their
quantification was performed on digital images with the
ImageJ program and AdobePhotoshop CS5. Results were
expressed as percentages with respect to the controls.Results and discussion
Melanoma cell exposure to B-RAF, MEK and AurkA
inhibitors
A375 (BRAFV600E) cell proliferation rates were assessed
upon exposure to the different inhibitor drugs alone and
in combination. As shown in Figure 1A, A375 cell prolifer-
ation rates were, as expected, reduced with B-RAF inhibi-
tor alone and the combined B-RAF inhibitor plus MEK
inhibitor. AurkA inhibitor in combination with B-RAF in-
hibitor and as a triple combination with B-RAF plus MEK
inhibitors also reduced cell proliferation rate, although it
was not very effective on cell proliferation rate, as single
agent (Figure 1A). This suggests combined B-RAF/AurkA
inhibition might be an alternative to B-RAF/MEK inhib-
ition and that triple B-RAF/MEK/AurkA inhibitor therapy
could be considered as a therapeutic option. Interestingly,
the MEK plus AurkA inhibitor combination demonstrated
higher anti-tumor efficacy than the B-RAF plus MEK in-
hibitor combination. This finding seems to suggest that a
MEK/AurkA combination could represent an alternative
treatment strategy for melanoma patients without B-RAF
mutations.
To confirm that B-RAF and MEK inhibitors were inhi-
biting their respective proteins, we analyzed the expression
of c-Myc, a downstream protein of B-RAF/MEK activated
by the MAPK pathway [36]. A reduction in c-Myc protein
levels in A375 melanoma cells was observed after 72 hours
of exposure to B-RAF inhibitor plus MEK inhibitor, MEK
Figure 1 (See legend on next page.)
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Figure 1 Effect of different drugs on melanoma cell proliferation. Proliferation curves of A375 melanoma cells as generated by xCELLigence
RTCA seeding 1×103 cells/well in E-16-well plates. Cells were allowed to grow for 48 hours in complete medium before adding the indicated
inhibitors, used as single agents or in different combinations, all used at 30 nM concentration except for the AurkA that was tested at 1 μM
concentration. Cell growth was monitored for an additional 72 hours. Data are the mean + SD of one experiment, performed in triplicate
(A). Western blot analysis of c-Myc (B) and p53 (C) in melanoma cells upon different single and combined treatment at 72 hours.
***indicated P-value ≤ 0.005.
Figure 2 Effect of different drugs on melanoma cell growth in human 3D tissues. H&E (a); S-100 (b) and Ki-67 (c) staining of representative
sections from 3D tissues at day 0 culture. H&E (a) staining showed a top bright red layer representing the epidermis; a successive layer of cells
with dark blue nuclei consisting of the melanocyte layer and a bottom largely unstained layer representing the dermal stratum (A); representative
sections from non-treated and drug-treated 3D tissues, stained with H&E (a, d ,g, l), S-100 (b, e, h, m) and Ki-67 (c, f, i, n) at day 9 (B) and at
day 12 (C); H&E, and S-100 staining of day 12 no-treated at different magnification (D) and a dermal stratum representative section from all 3D
tissues, stained with S-100 (E). The dimension bar was reported.
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ation (Figure 1B).
The tumor protein p53 has been reported to be phos-
phorylated by AurkA, leading to its increased degradation
and downregulation of checkpoint-response pathways
[37]. Thus, to confirm that the AurkA inhibitor (MLN8054)
was inhibiting AurkA protein, we analyzed p53 protein
level in the A375 cell line. After 72 hours of drug expos-
ure, p53 protein level increased (Figure 1C). Levels of p53
were lower in cell lines exposed to double and triple drug
combinations compared with single agent AurkA inhibi-
tor, suggesting that the down-regulation of c-Myc, follow-
ing B-RAF/MEK inhibition, affected p53 protein levels.
AurkA inhibitor enhanced the effect of B-RAF and MEK
inhibitors on melanoma cell growth in a 3D human skin
reconstruction model
In order to further investigate the effect of AurkA inhib-
itors on melanoma cell growth, we used a more complex
3D human skin reconstruction model using A375 mel-
anoma cells. Such a model offers the advantage of being
more representative of the in vivo situation, given that
cells may interact with other cells and act in a different
manner when grown within a 3D matrix, while there are
significant differences in cellular architecture and physi-
ology between mouse and human skin e.g. melanocytes
are mostly localized in hair follicles in mouse skin and
have distinct biological properties that may differ from
those of humans, in which melanocytes are mainly lo-
cated at the basal layer of the epidermis.
At baseline (day 0), H&E staining of cultures revealed
keratinocytes in the upper epidermal layer, organized in
the basal, spinous, granular, and corneum stratum; a sec-
ond distinct layer of cells was represented by A375 melan-
oma cells (Figure 2A). At this early time point, this layer
was only a few cells thick, with these cells distinguished byFigure 3 Quantitative analysis of Ki-67 immune-histochemical results. Q
differences in the expression of Ki-67 in 3D tissue cultures treated with diff
(non-treated) at epidermal/dermal junction site (A) and in dermal stratum
respect to control. **p ≤ 0.01vs control.their dark nuclear staining. A third distinct layer is
represented by dermal stratum consisting of fibroblast-
contracted collagen. Analysis of S-100 protein expression,
a marker of the melanocytic cell lineage, confirmed the
presence of melanoma cells in the tissues (Figure 2A).
In the control tissue, metastatic melanocytes proliferated
over time and developed nodules at the dermal/epidermal
junction by day 5 (data not shown), which were further
enlarged at days 9 (Figure 2B) and 12 (Figure 2C), as con-
firmed by their S-100 and Ki67 immunostaining. In con-
trast, in tissues treated with the triple drug combination
there were fewer tumor nodules close to the epidermis with
less invasion of the dermal structures at day 9 (Figure 2B).
Exposure to B-RAF inhibitor plus MEK inhibitor or MEK
inhibitor plus AurkA inhibitor provided results intermedi-
ate between control and the three drugs combined, as
showed in Figure 2B; however, less tumor nodules were
observed in tissues treated with the MEK plus AurkA in-
hibitors compared with B-RAF plus MEK inhibitors.
At day 12, the effect of the triple drug combination
on melanoma growth was more pronounced (Figure 2C).
Clusters of melanoma cells were detected on the other
side of the dermal stratum in non-treated tissue, as shown
in detail in Figure 2D, suggesting vertical growth tumor
development.
Interestingly, in all treated and non-treated tissues, in-
dividual proliferating melanoma cells were observed in-
filtrating the dermis, as suggested by their Ki-67 (data
not shown) and S-100 antigen expression (Figure 2E).
These cells showed a different morphology to those ob-
served at the dermal/epidermal junction. The small nest
cells were polygonal in shape and remained confined at
the junction site (Figure 2D, section a). In comparison,
the individual melanoma cells in the dermal stratum ap-
peared as spindle-shaped cells connected to one another
and forming a 3D-cellular network (Figure 2E). Theseuantitative analysis of the immunohistochemical results depicting the
erent drug combination or medium without drugs as control
(B). Results are expressed in percentage of immune-stained cells with
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able to escape the drug anti-tumor effect than small nest
melanoma cells localized at the epidermal/dermal junc-
tion. The observation that the drugs penetrated to the
other side of the tissues from the dermal stratum and
killed the small nest cells suggests that the ability of in-
dividual melanoma dermal cells to escape the drug ef-
fect was dependent on their intrinsic properties and not
on the dermal stratum being a barrier to drug exposure.
It has been previously reported that the epithelial-
to-mesenchymal transition (EMT) mechanism plays an
important role in promoting chemoresistance, invasion,
and stem cell-like properties [38,39]. The observed differ-
ent shape of the cells suggested a potential EMT in these
tissues, and it may explain the more resistant phenotype
of these cells to the drugs used. This provides support to
the idea that specific targeting of EMT could potentially
serve to decrease metastasis and overcome drug resist-
ance. However, further studies are needed to explain the
potential role of these cells.
Observations at both the epidermal/dermal junction and
the dermal stratum were also quantified with the densito-
metric results shown in Figure 3A and B, respectively. To
determine whether the decrease in S100-positive cells
might account for the inhibition of melanocyte prolifera-
tion, tissue sections were stained with the proliferation
marker Ki-67. This clearly revealed a decrease in the num-
ber of proliferative cells at the epidermal/dermal junction
site after triple drug exposure compared with control.
Intermediate results were obtained with both double drug
combinations. Quantitative analysis of the Ki-67 immuno-
histochemical results are presented in Figure 3A. No sig-
nificant differences were found in Ki-67 immunostained
cells after triple or either double drug treatments at the
dermal stratum compared with control (Figure 3B).
Conclusions
Our findings provide new prospects for melanoma re-
search, suggesting that combined B-RAF/AurkA inhib-
ition might offer a therapeutic alternative to B-RAF/MEK
inhibition for B-RAF mutated melanomas, while a MEK/
AurkA inhibitor combination could represent a possible
option for patients without B-RAF mutations. Moreover,
for the first time, we have shown that a triple drug com-
bination comprising of inhibitors of B-RAF, MEK and
AurkA offers increased efficacy against melanoma cell
growth and might be considered as a potential treat-
ment strategy for enhancing clinical response in melan-
oma. However, although this triple drug combination was
more effective as anti-tumor therapy at the epidermal/der-
mal junction, it seemed to leave individual S-100 and Ki-
67 positively stained spindle-shaped melanoma cells alive
and proliferating in the dermal stratum, which may re-
sult in drug resistance and disease recurrence. Molecularcharacterization of these dermal cells may be critical in
providing additional tools for the development of novel
therapeutic strategies.
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